Initial dose: 20 mg orally once a day Maintenance dose: 5 mg to 40 mg orally once a day Comments: 1. Response to therapy should be estimated from preapheresis LDL-C levels. 2. This drug may be used as an adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if … See more
WEBMay 1, 2019 · High-quality evidence from RCTs recommends that patients 40 to 75 years of age without diabetes who are at intermediate risk with LDL-C levels of 70 to 189 mg per dL …
WEBMay 23, 2023 · Rosuvastatin is a statin medication used as a lipid-lowering agent. The FDA-approved indications are homozygous familial hypercholesterolemia, hyperlipidemia, mixed … Published: 2023/05/23
Published: 2023/05/23
DA:7PA:38MOZ Rank:8
Rosuvastatin (Oral Route) Proper Use - Mayo Clinic
WEBTo use: Open the capsule and empty the contents into a 60-milliliter (mL) catheter syringe. Add 40 mL of water. Do not use any other liquid. Replace the plunger and shake the syringe …
WEBPCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice … Created Date: 6/8/2019 2:27:58 PM
Created Date: 6/8/2019 2:27:58 PM
DA:49PA:43MOZ Rank:5
Comparing Guideline Recommendations of Statin Use For …
WEBOct 4, 2022 · A. Quick Takes. Implementation of the 2022 USPSTF guideline for statin therapy for primary prevention would reduce the opportunity for ASCVD risk reduction in a …
DA:76PA:42MOZ Rank:70
Rosuvastatin: Uses, Dosage, Side Effects, Warnings
WEBJun 1, 2019 · For persons with a 7.5% to 20% risk, they recommend a moderate-intensity statin for most patients to target a 30% to 49% reduction in LDL cholesterol. Finally, if the …
DA:22PA:53MOZ Rank:87
ACC/AHA Release Updated Guideline on the Treatment of …
WEBAug 15, 2014 · This updated guideline focuses on reducing the risk of ASCVD in four statin benefit groups: (1) persons with clinical ASCVD (i.e., acute coronary syndromes, or a …
DA:15PA:50MOZ Rank:15
Rosuvastatin: A Review of the Pharmacology and Clinical …
WEBFeb 1, 2012 · Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue …
